Skip to content

Regulators and organisations

FDA (United States) Latest

US Food and Drug Administration decisions, designations, guidance and advisory committee activity on psychedelic medicines.

2 picks1 in the past 30 days20 collected in total

Updated

Top picks for FDA (United States)

9 NovMon1–2
  1. Psychedelic Alpha80

    Compass Pathways submits COMP360 psilocybin new drug application to FDA for treatment-resistant depression

    Compass Pathways announced it has submitted a new drug application to the FDA for its COMP360 psilocybin for treatment-resistant depression (TRD). The FDA is now reviewing three psychedelic applications, after Resilient Pharmaceuticals resubmitted its MDMA for PTSD application this summer and Usona Institute filed its psilocybin for major depressive disorder (MDD) package more recently. Compass said its package includes data from more than 1,000 participants, and the company is targeting an H1 2027 launch.

    Why it matters: With three psychedelic applications now before the FDA, the agency's next steps on COMP360 will show how it handles a package drawn from more than 1,000 participants.

5 OctMon
  1. FDA: press announcements (US)62

    FDA seeks public input on early-phase ibogaine trial design

    The US Food and Drug Administration has issued a request for information on approaches it is considering for the design of early-phase clinical trials of ibogaine drug products, and is seeking public comment.

    Why it matters: The request sets out the protocol questions the agency wants answered, including a starting dose cap, so researchers and sponsors can see what evidence the FDA expects before early-phase ibogaine trials proceed.